Transverse Myelitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Transverse Myelitis Market Outlook

Thelansis’s “Transverse Myelitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Transverse Myelitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Transverse Myelitis Overview

Transverse myelitis is a neurological disorder characterized by inflammation across both sides of one level or segment of the spinal cord, leading to damage or destruction of myelin, the fatty protective substance covering nerve cell fibres. This damage creates scars that disrupt communication between nerves in the spinal cord and the rest of the body. While most affected individuals will have only one attack, some may have multiple. It can be the initial symptom of multiple sclerosis (MS) or neuromyelitis optica (NMO). The cause of transverse myelitis is not fully understood, but it is believed to result from an autoimmune reaction triggered by a viral or bacterial infection. In approximately 50% of cases, transverse myelitis is preceded by an infection. Various viral infections, including varicella zoster, herpes simplex, cytomegalovirus, Epstein-Barr, influenza, echovirus, HIV, hepatitis A, and rubella, and bacterial infections such as Mycoplasma pneumonia and skin infections, have been associated with transverse myelitis. It is categorized as either complete or partial, depending on the extent of its symptoms. Complete transverse myelitis is characterized by more severe symptoms, indicating the involvement of all spinal cord tracts and resulting in loss of corticospinal, sensory, and autonomic functions below the level of the lesion. In contrast, patients with partial myelitis may present with Brown-Séquard hemicord syndrome, which causes ipsilateral corticospinal dysfunction and posterior columnar and contralateral spinothalamic dysfunction.

• It can occur in people of all ages and races but tends to affect younger individuals most frequently, particularly those aged between 10 and 19 or between 30 and 39. Currently, there is no effective cure for transverse myelitis.
• Transverse myelitis has an annual incidence rate of 1.34 to 4.60 cases per million. However, this incidence rate increases to 24.6 cases per million when acquired demyelinating diseases such as multiple sclerosis (MS) and neuromyelitis optica (NMO) are also considered.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: